NCT06734832View on ClinicalTrials.gov

Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)

PHASE3RecruitingINTERVENTIONAL
Enrollment

8,000

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Hand, Foot, and Mouth Disease（HFMD)
Interventions
BIOLOGICAL

bivalent enterovirus vaccine (Vero cell), inactivated

Two doses are administered with a one-month interval between each dose.

BIOLOGICAL

Enterovirus Type 71 Vaccine (Vero Cell), Inactivated

Two doses are administered with a one-month interval between each dose.

Trial Locations (4)

650000

RECRUITING

Guangdong Provincial Center for Disease Control and Prevention, Guangdong

Unknown

RECRUITING

Anhui Provincial Center for Disease Control and Prevention, Hefei

RECRUITING

Fujian Provincial Center for Disease Control and Prevention, Fujian

RECRUITING

Hubei Provincial Center for Disease Control and Prevention, Hubei

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY